Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Michael McGarrity, William Moffitt, William White, Mark Slezak, and Others

Premium

Nanosphere said this month in its fourth-quarter financial report that it has promoted Michael McGarrity to succeed William Moffitt as its new president and CEO.

McGarrity previously was vice president of sales and marketing and chief commercial officer at the Northbrook, Ill.-based firm. Moffitt had led Nanosphere as CEO and president since his appointment in 2004.

As part of the shakeup, Moffitt, William White, Mark Slezak, and Roy Davis all resigned from Nanosphere's board of directors. The company said it has appointed Sheli Rosenberg, Michael Ward, and McGarrity to replace them. Rosenberg, who served on Nanosphere's board from 2002 to 2012, will be its new chair.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.